BioPharma Credit, a life-sciences investment trust, offers a tempting yield. But the dangers may be high when the credit cycle turns.
Articles written by Max King
Miton Global hunts for rare treasures in the remoter reaches of the market – all you need to do is buy in, says Max King.
Haranguing company managers is a lucrative business for those who like to get stuck in, says Max King.
The UK housing market is in the doldrums, but commercial property still has a lot to offer, says Max King.
For private equity companies, raising the cash was the easy bit, says Max King – now what to invest it in?
The broader equity market made little progress in the first half of 2018, but those who followed our investment trust recommendations have reason to be pleased, says Max King.
The world’s problems can be solved – and the Impax Environmental Markets investment trust is well placed to profit from fixing them.
Despite having a tough year, the outlook for funds investing in PFI and support services is improving, says Max King.
Universities are converting from final-salary to defined-contribution pension schemes. Academics should be grateful, says Max King.
The Witan Investment Trust is geographically diversified and boasts a growing dividend, says Max King.